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Streszczenie
Wielkokomórkowe chłoniaki rozlane B-komórkowe (DLBCL, diffuse large B-cell lymphoma)
są najczęstszymi nowotworami układu chłonnego u ludzi dorosłych, a zarazem niezwykle
heterogenną grupą chorób. Ich molekularną substrukturę odzwierciedlają w znacznym stopniu
biologiczne uwarunkowania, scharakteryzowane uprzednio na podstawie globalnego profilu
ekspresji genów i algorytmu consensus clustering w dwóch niezależnych grupach chorych.
Badania te wykazały, że w obrębie chłoniaków DLBCL można wyróżnić trzy podtypy o od-
miennej genetycznej charakterystyce. Profil ekspresji najliczniejszej ze zidentyfikowanych grup,
nazwanej „BCR” (B-cell receptor signaling), charakteryzowała nadekspresja genów kodują-
cych białka receptora B-komórkowego i kaskady transdukcji sygnału z tego receptora, w tym
SYK (Spleen Tyrosine Kinase) oraz niektóre B-komórkowe czyniki transkrypcyjne, w tym
BCL6. W grupie “BCR” obserwowano również częstsze niż w innych podtypach translokacje
regionu 3q obejmujące locus BCL6. Obserwacje te sugerowały, że wzrost i proliferacja komó-
rek tego molekularnego podtypu DLBCL może zależeć od ścieżek sygnałowych zależnych od
receptora BCR i/lub od programu transkrypcyjnego BCL6. W celu zbadania tej hipotezy,
przeprowadzono badania oceniające rolę tonicznego sygnału zależnego od kinazy SYK i konse-
kwencji inhibicji transdukcji tego sygnału in vitro, mechanizmy kontrolujące aktywność kina-
zy SYK, mechanizmy transkrypcyjne czynnika transkrypcyjnego BCL6 i konsekwencje wyłą-
czenia funkcji BCL6 in vitro oraz interakcję pomiędzy funkcją czynnika transkrypcyjnego
BCL6 i aktywnością receptora BCR w chłoniakach o molekularnej charakterystyce „BCR”.
W przeprowadzonych badaniach wykazano, że zarówno linie komórkowe o charakterystyce
molekularnej odpowiadającej chłoniakom typu „BCR”, jak i pierwotne izolowane komórki
nowotworowe pobrane od części chorych, wykazują konstytutywną toniczną aktywność kinazy
SYK i jej bezpośredniego substratu, białka adaptorowego BLNK (B-cell linker protein).
Zastosowanie wysokospecyficznego, ATP-kompetycyjnego inhibitora R406 in vitro prowadziło
do zahamowania tonicznej i aktywowanej ligandem aktywności receptora BCR (mierzonej
jako fosforylacja BLNK84) i prowadziło do apoptozy badanych komórek. Badania te wska-
zują, że SYK-zależny toniczny sygnał receptora BCR jest ważnym czynnikiem warunkującym
proliferację komórek chłoniakowych o molekularnej charakterystyce „BCR” i może być tera-
peutycznym celem dla małocząsteczkowego inhibitora SYK. Wykazano ponadto, że komórki
wrażliwe na działanie tego inhibitora można zidentyfikować na podstawie ich globalnego
profilu ekspresji genów.
Kluczowa rola SYK w transdukcji i amplifikacji sygnału z receptora BCR sugerowała, że
aktywność tej kinazy pozostaje pod ścisłą fizjologiczną kontrolą. W drugiej części badań wyka-
zano, że kinaza ta jest substratem dla tkankowo-swoistej izoformy fosfatazy PTPROt (Protein
Tyrosine Phosphatase, Receptor–type O, truncated). Wymuszona ekspresja PTPROt pro-
wadziła do zahamowania fosforylacji SYK indukowanej ligandem i dystalnej blokady w trans-
dukcji sygnału do kinaz ERK1/2. Nadekspresja PTPROt prowadziła również do zahamowa-
nia proliferacji komórek, a w konsekwencji do ich apoptozy. Apoptotyczną śmierć komórek
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wskutek nadekspresji PTPROt obserwowano również przy braku aktywacji receptora BCR, co
sugeruje, że fosfataza ta reguluje także toniczną aktywność SYK.
Drugą podstawową charakterystyką chłoniaków DLBCL typu „BCR” jest nadekspresja czyn-
nika transkrypcyjnego BCL6 i częstsze translokacje dotyczące tego onkogenu. Obserwacje te
sugerowały, że ekspresja BCL6 może być dodatkowym czynnikiem warunkującym wzrost
w tym podtypie molekularnym DLBCL. Chłoniaki DLBCL zależne od szlaków molekularnych
regulowanych przez BCL6 powinny wykazywać skoordynowany profil ekspresji genów kontro-
lowanych przez BCL6, odrębny od profilu chłoniaków niezależnych od BCL6. W celu zbadania
tej hipotezy, przeprowadzono genomową analizę regionów promotorowych regulowanych przez
BCL6. Wykazano, że geny kontrolowane przez BCL6 były istotnie częściej reprezentowane
w grupie „BCR”. W badaniach przeprowadzonych na liniach komórkowych, proapoptotyczny
efekt inhibicji funkcji BCL6 peptydem BPI (BCL6-peptide inhibitor) obserwowano wyłącznie
w liniach typu „BCR”.
Unikalna wrażliwość linii komórkowych typu „BCR” na inhibicję BCL6 sugerowała istnienie
nieznanego dotychczas związku między działaniem tego czynnika transkrypcyjnego a sygna-
łem zależnym od receptora BCR. Celem zbadania postulowanego związku, przeanalizowano
wpływ czynnika transkrypcyjnego BCL6 na poziom transkrypcji genów kodujących białka
biorące udział w proksymalnych etapach transdukcji sygnału z BCR. W izolowanych, wysoko
oczyszczonych frakcjach prawidłowych limfocytów, w tym naiwnych, germinalnych i komór-
kach pamięci oraz w dwóch grupach pacjentów z DLBCL, ekspresja transkryptu BCL6 pozo-
stawała w odwrotnej korelacji z ekspresją transkryptu PTPROt. W dalszych badaniach funk-
cjonalnych wykazano, że BCL6 jest represorem transkrypcji genu PTPROt i bezpośrednio
wiąże się z jego regionem promotorowym. Wyłączenie funkcji BCL6 poprzez mechanizm inter-
ferencji RNA powodowało nadekspresję PTPROt, defosforylację SYK oraz zahamowanie trans-
dukcji sygnału z receptora BCR tylko w liniach komórkowych typu „BCR”. BCL6 kontrolował
promotor PTPROt również w prawidłowych izolowanych germinalnych limfocytach B, wska-
zując, że BCL6 jest fizjologicznym regulatorem przekazywania sygnału z BCR. Przeprowadzo-
ne badania identyfikują dotychczas nieznaną funkcję BCL6 w regulacji aktywności komplek-
su receptora BCR oraz wskazują na istotny mechanizm wrażliwości na inhibicję BCL6,
zależny od zahamowania aktywności kinazy SYK. Badania te sugerują również, że skojarzone
zahamowanie szlaków sygnałowych zależnych od BCL6 i receptora B-komórkowego może mieć
charakter synergistyczny u chorych z chłoniakami DLBCL o charakterystyce molekularnej
“BCR”.
Słowa kluczowe: Wielkokomórkowe chłoniaki rozlane B-komórkowe, Mikromacierze DNA,
Profil ekspresji genów, Receptor B-komórkowy, SYK, PTPROt, BCL6, Terapia celowana
Summary
Diffuse large B-cell lymphomas (DLBCL) are the most common lymphoid malignancy in
adults and an extremely heterogeneous group of disorders. To delineate functionally relevant
DLBCL subsets, consensus clustering methods were previously applied to the transcriptional
profiles of two large independent series of primary DLBCL to identify the dominant substruc-
ture a priori. The obtained consensus clusters were highly reproducible and included a group
of DLBCL, termed B-cell receptor (“BCR”) that was characterized by increased expression of
components of the BCR signaling cascade including SYK (Spleen Tyrosine Kinase) and
certain B-cell specific transcription factors such as BCL6; these DLBCL also exhibit more
frequent translocations of the BCL6 locus. These observations suggested that the “BCR”
molecular category of DLBCL might be reliant on either, or both, BCR signaling and BCL6
transcriptional program. To test this hypothesis, the studies were undertaken to specifically
investigate the role of tonic SYK-dependent signaling in “BCR”-type DLBCL and the biologi-
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cal consequences of the pathway inhibition in vitro, mechanisms controlling SYK activity, role
of transcriptional program controlled by BCL6 and the biological consequences of its inhibi-
tion in vitro and relationship between BCL6 mediated repression and SYK-dependent signa-
ling in “BCR”-type DLBCL.
These studies demonstrated that inhibition of the BCR signaling pathway with an ATP-
competitive inhibitor of SYK, R406, induced apoptosis of the majority of examined DLBCL
cell lines and primary DLBCL in vitro. R406-sensitive DLBCL cell lines and primary tumors
exhibited tonic activity of SYK and its direct substrate, B-cell linker protein (BLNK). In these
R406-sensitive lines and primary tumors, R406 specifically inhibited both tonic and ligand-
induced BCR signaling (SYK-dependent phosphorylation of BLNK). Therefore, SYK-depen-
dent tonic BCR signaling is an important and potentially targetable survival pathway in some,
but not all, DLBCL. In addition, R406-sensitive DLBCL can be identified by their transcrip-
tional profiles.
Consistent with critical role of SYK in modulating BCR signaling, its activity remains under
tight control. SYK is a major substrate of a tissue-specific and developmentally regulated PTP,
PTP receptor–type O truncated (PTPROt). The overexpression of PTPROt inhibited BCR-
-triggered SYK tyrosyl phosphorylation and downstream signaling events, including extracel-
lular signal–regulated kinase (ERK1/2) activation. PTPROt overexpression also inhibited
lymphoma cell proliferation and induced apoptosis in the absence of BCR cross-linking, sugge-
sting that the phosphatase modulates tonic BCR signaling.
“BCR” tumors also exhibit more abundant BCL6 expression and more frequent BCL6 trans-
locations, suggesting that these tumors likely rely on BCL6 transcriptional program. It could
be predicted therefore that DLBCL dependent upon BCL6-regulated pathways would exhibit
coordinate repression of BCL6 target genes. For this reason, genomic array ChIP-on-chip was
utilized to identify the cohort of direct BCL6 target genes. In primary DLBCL classified on the
basis of gene expression profiles, these BCL6 target genes were differentially regulated in
“BCR” tumors. In a panel of DLBCL cell lines analyzed by expression arrays and classified
according to their gene expression profiles, only “BCR” tumors were highly sensitive to the
BCL6 peptide inhibitor (BPI). These studies identify a discrete subset of DLBCL that are
reliant upon BCL6 signaling and uniquely sensitive to BCL6 inhibitors.
Since the same transcriptionally defined subset of DLBCL relies upon SYK-dependent BCR
signaling and exhibits coordinate BCL6-mediated transcriptional repression, the relationship
between these two processes was subsequently explored. In transcriptionally profiled normal
B-cell subsets (naïve, germinal center [GC], and memory B cells) and in primary DLBCL,
there were reciprocal patterns of expression of BCL6 and the SYK tyrosine phosphatase,
PTPROt. BCL6 repressed PTPROt transcription via a direct interaction with functional
BCL6 binding sites in PTPROt promoter. Enforced expression of BCL6 in normal naïve B
cells and RNAi-mediated depletion of BCL6 in GC B-cells directly modulated PTPROt expres-
sion. In “BCR”-type DLBCL, BCL6 depletion increased PTPROt expression and decreased
phosphorylation of SYK and the downstream adaptor protein, BLNK, demonstrating that
BCL6 augments BCR signaling. Since BCL6 and SYK are both promising therapeutic targets
in many DLBCL, combined inhibition of these functionally related pathways warrants further
study.
Key words: Diffuse large B-cell lymphomas, Microarray gene expression profiling, B-cell
receptor, SYK, PTPROt, BCL6 transcriptional program, Targeted therapy
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List of abbreviations
BCR: B-cell receptor
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BPI: BCL6 peptide inhibitor
ChIP: chromatin immunoprecipitation
CR: complete response
CT: threshold cycle
CLL/SLL: chronic lymphocytic leukemia/small
lymphocytic lymphoma
DLBCL: diffuse large B-cell lymphoma
ERK : extracellular signal–regulated kinase
ES: enrichment score
FDR: false discovery rate
FL: follicular lymphoma
GC: germinal center
GO: Gene Ontology
GSEA: gene-set enrichment analysis
“HR”: “Host Response” Consensus Cluster
IC50: inhibitory concentration for 50% cells
Ig: immunoglobulin
IPI: International Prognostic Index
ITAM: immunoreceptor tyrosine-based activa-
tion motif
MALT: mucosa-associated lymphoid tissue
MCL: mantle cell lymphoma
PI : propidium iodide
PTK: protein tyrosine kinase
PTP: protein tyrosine phosphatase
PTPROt : protein tyrosine phosphatase receptor
type O, truncated
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay
NHL: non-Hodgkin lymphoma
“OxP” : “Oxydative Phosphorylation” Consen-
sus Cluster
PR: partial response
QChip: quantitative single-locus chromatin im-
munoprecipitation
SD: standard deviation
SHM: somatic hypermutation
SNR: signal-to-noise ratio
SYK: spleen tyrosine kinase
TSS: transcription start site
Introduction
Heterogeneity of DLBCL
Diffuse large B-cell lymphomas (DLBCL) are
the most common lymphoid malignancies in adults
[1]. DLBCL are thought to arise from normal anti-
gen-exposed B cells that have migrated to or
through germinal centers (GC) of lymph nodes or
secondary lymphoid organs [2]. Like normal GC B
cells and their progeny, DLBCL have somatic hy-
permutations (SHM) of immunoglobulin receptor
variable (v) region genes [3, 4]. Physiologically,
SHM occurs during GC B-lymphocyte development
and generates antibody diversity and increases an-
tigen affinity. As this process involves generation
of transient double strand DNA brakes, SHM also
facilitates chromosomal translocations and mutagen-
esis that deregulate expression of certain oncogenes,
such as BCL6, BCL2, or cMYC [1, 3, 5, 6]. A subset
of DLBCL also exhibits aberrant SHM of genes that
are not targeted by this editing process in normal
GC B cells [7]. Finally, a significant percentage of
DLBCL lack known genetic abnormalities.
The pathogenetic heterogeneity of this disease
is reflected by the clinical variability in the disease
course. Although approximately 50–55% of DLBCL
patients can be cured with modern therapy, the
remaining patients succumb to their disease [1].
Clinical prognostic models such as the Internation-
al Prognostic Index (IPI) can be used to robustly
identify patients who are less likely to be cured with
standard chemotherapy [8]. Although such models
were proven extremely useful clinically, they pro-
vide solely descriptive risk assessment and do not
provide specific insights regarding tumor cell biol-
ogy, alternative more effective treatment strategies
or novel therapeutic targets.
Molecular substructure of DLBCL
Striking clinical and genetic heterogeneity sug-
gest additional substructure within DLBCL. To
unveil this molecular substructure in an unbiased
way, a genome-wide genetic profiling and multiple
clustering methods (hierarchical clustering, prob-
abilistic clustering, and self-organizing maps) have
been previously applied to 176 newly identified
DLBCL patients [9]. Using an approach that as-
sessed an agreement between the 3 clustering al-
gorithms and selected the most stable numbers of
clusters with each algorithm, 3 biologically robust
clusters were defined that were independent of pri-
or distinctions, such as Cell of Origin (COO) [9–11].
Within each cluster, overexpressed genes and path-
ways were identified and analyzed to indicate the
most likely biological background of the subset and
provide clues to lymphomagenesis. The first clus-
ter, termed “Oxidative Phosphorylation” (OxP),
showed increased expression of genes involved in
mitochondrial function, electron transport, regula-
tion of apoptosis, and proteosomal degradation [9].
Genetically, these tumors were more likely than
others to harbor the t(14;18) involving BCL2 [9, 12].
The signature of the second cluster, termed “Host
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Response” (HR) was largely determined by the host
inflammatory response, rather than tumor cells
themselves. In HR tumors, overexpressed genes
included those involved in T-cell receptor signal-
ing, CD2, T-cell and natural killer (NK) cell activa-
tion, monocyte/macrophage activators, complement
pathway proteins, cytokine receptors, tumor necro-
sis factor (TNF)–related proteins, and adhesion
molecules [9]. The third cluster, accounting for
more than 50% of tumors, was characterized pri-
marily by increased expression of components of
the BCR signaling cascade and certain B-cell–spe-
cific transcription factors, such as BCL6. Of note,
these tumors also had more frequent standalone
BCL6 translocations, suggesting that these tumors
likely rely on the BCR signaling cascade and BCL6
transcriptional program and that these pathways
could represent novel rational treatment targets [12].
Tonic BCR signaling in normal
B-cell development and in DLBCL
Emerging data highlight the important role of
B-cell receptor (BCR)-mediated survival signals
during normal B-cell development and in certain B-
cell lymphomas. BCR engagement induces recep-
tor oligomerization and phosphorylation of Iga and
b immunoreceptor tyrosine-based activation motifs
(ITAMs) by SRC family kinases [13–15]. ITAM
phosphorylation results in the recruitment and ac-
tivation of SYK, a protein tyrosine kinase (PTK) that
initiates downstream events and amplifies the orig-
inal BCR signal [13–16]. Although BCR signaling
is generally thought to depend on ligand-induced
aggregation, additional studies highlight the impor-
tant role of “tonic” BCR maintenance or survival
signals in the absence of receptor engagement [14,
17–19]. Lam et al. first demonstrated that the induc-
ible loss of murine BCR resulted in the death of
peripheral B cells, highlighting the requirement for
continued BCR expression in viable B cells [18]. In
follow-up studies, the selective excision of the Iga
ITAM and ablation of Iga signaling led to the loss
of mature B cells, further emphasizing the role of
tonic BCR signaling in B-cell survival [17]. Consist-
ent with its central role in the BCR signaling, SYK
activity is tightly regulated by BCR-associated
phosphorylation and Cbl-mediated proteasomal
degradation. Additional studies highlight the likely
role of PTPs in tonic BCR signaling, demonstrat-
ing that BCR-proximal PTKs can be activated by the
phosphatase inhibitor pervanadate/H2O2 without
BCR cross-linking [14, 15, 19, 20].
Several lines of evidence suggest that many B-cell
lymphomas depend on B-cell receptor (BCR)–me-
diated survival signals as well. Most B-cell lympho-
mas retain BCR expression and limit immunoglob-
ulin (Ig) loci translocations to nonproductively re-
arranged Ig alleles [21]. In addition, B-cell lympho-
mas with ongoing somatic hypermutation rarely
exhibit loss of BCR expression [21]. Furthermore,
treatment with anti-idiotypic antibodies uncommon-
ly leads to the emergence of BCR-negative lympho-
ma variants [21]. Overexpression of multiple BCR
signaling components including central regulator
and amplifier of the cascade (SYK) in the “BCR”-
-type tumors, suggested that these tumors are more
likely to be reliant on BCR pro-survival signaling.
BCL6 in DLBCL pathogenesis
BCL6 is a BTB/POZ domain transcription re-
pressor that is the master regulator required for
normal germinal center development and expressed
by the majority of normal GC B cells and a subset
of DLBCL [22, 23]. BCL6 favors the survival and
proliferation of GC B cells, which undergo somatic
hypermutation of Ig variable regions and Ig class
switch recombination; down-regulation of BCL6 is
necessary for post-GC B cell maturation [24–27].
Deregulation of BCL6, by chromosomal transloca-
tion or aberrant somatic hypermutation is the most
common genetic abnormality in DLBCL [28]. Con-
clusive evidence for the oncogenic role of BCL6
comes from murine models in which constitutive
BCL6 expression results in the development of
a lymphoid malignancy resembling DLBCL [29, 30].
Although deregulated BCL6 clearly plays a patho-
genetic role in a subset of human DLBCL, other
DLBCL may simply express this transcriptional
repressor because they are derived from normal
BCL6+ GC B cells. Identification of BCL6-depend-
ent tumors has important therapeutic implication
because a recently described specific BCL6 peptide
inhibitor (BPI) inhibits the growth of some but not
all DLBCL [31, 32]. This inhibitor specifically in-
hibits recruitment of BCL6 corepressors such as
BCoR, NCoR and SMRT, disrupts BCL6-mediated
repression and establishment of silenced chroma-
tin and reactivates natural BCL6 target genes. In-
traperitoneal injection of BPI to mice prevent GC
formation upon T-cell dependent antigen challenge,
demonstrating that BPI abrogates BCL6 function in
vivo and mimics BCL6 -/- phenotype [31].
Taken together, these observations suggest-
ed that the “BCR”-type comprehensive transcrip-
tional signature is likely related to biological and
functional foundations. It could be hypothesized
therefore, that this specific molecular tumor cate-
gory would be reliant on these pathways, and that
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targeted inhibition of BCR signaling and/or BCL6
would be therapeutically beneficial. For these rea-
sons, the studies were performed to investigate the
specific aims as outlined below.
Aims of the study
1. To investigate the role of tonic pro survival
SYK-dependent signaling in “BCR”-type
DLBCL and biological consequences of its in-
hibition in vitro,
2. To investigate the mechanism controlling SYK
activity,
3. To investigate the role of transcriptional pro-
gram controlled by BCL6 and the biological
consequences of its inhibition in vitro,
4. To explore the relationship between BCL6-
-mediated repression and SYK-dependent sig-
naling in “BCR”-type DLBCL.
Material and Methods
Cell culture
The DLBCL cell lines DHL4, DHL6, DHL8,
DHL10, Wsu-NHL, Karpas 422 (K422), OCI LY1,
LY4, LY7, LY18, LY19, Pfeiffer, and Toledo were
cultured in RPMI 1640 medium (Mediatech, Hern-
don, VA) supplemented with 10% fetal calf serum
and 2 mM glutamine. DLBCL cell lines LY3 and
LY10 were cultured in Iscove modified Dulbecco
medium (IMDM) (Invitrogen, Grand Island, NY)
supplemented with 20% human serum (Gemini Bio-
Products,West Sacramento, CA) and 2 mM
glutamine. All the cells were maintained at 37°C in
5%CO2. The cell lines, which were all mycoplas-
ma-free, were obtained from the following sourc-
es: Pfeiffer and Toledo, American Tissue Culture
Collection (ATCC, Manassas, VA); DHL4, DHL6,
DHL8, DHL10, Wsu-NHL, Karpas422, Ly19, Deut-
sche Sammiung von Mikroorganismen und Zellkul-
turen GmbH (DSMZ, Braunschweig, Germany); and
OCI Ly1, Ly3, Ly4, Ly7, Ly10, Ly18, Ontario Can-
cer Institute (University of Toronto, Toronto, ON).
Consensus cluster assignment to cell lines
The DLBCL cell lines were assigned to consen-
sus clusters [9] using their transcriptional profiles
and a recently described ensemble classifier which
combines by majority voting the class assignments
of 14 independent predictive algorithms [33, 34].
Treatment with R406
The small molecule SYK inhibitor, R406, [35]
was a gift from Rigel (San Francisco, CA). R406 was
dissolved in DMSO at a concentration of 10 mM and
stored at -80°C. After thawing, the R406 stock so-
lution was kept in a desiccator at room temperature
for up to 1 week. DLBCL cell lines were treated
with 1 or 4 µM R406 or vehicle alone for 72 hours.
Analysis of cellular proliferation
and apoptosis
Cellular proliferation was determined by MTT
assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) assay (Roche Diagnostics,
Indianapolis, IN) using standard protocols. For each
cell line, IC50 was calculated using GraphPad Prism
4 software (GraphPad Software, San Diego, CA).
DLBCL cell line apoptosis was analyzed using an-
nexin V-FITC/propidium iodide (PI) staining (An-
nexin V-FITC apoptosis detection KIT I; BD Bio-
sciences, San Jose, CA). In these experiments, all
cells were analyzed and the annexin V+, annexin
V+/PI+ and PI+ cells were considered apoptotic.
Surface Ig cross-linking
Goat anti–human IgG was purchased from Jack-
son ImmunoResearch Laboratories (West Grove,
PA). Cells (5 × 106) in 0.5 mL RPMI were stimu-
lated with goat anti–human IgM and IgG for indi-
cated periods of time.
Phospho-specific flow cytometry
Intracellular phospho-specific flow cytometry
was performed as previously described [36] accord-
ing to the manufacturer’s instructions. In brief,
2 × 106 cells were resuspended in 1 mL cold PBS
plus 1% FCS and left untreated or stimulated with
goat anti–human IgG or IgM at 37°C as indicated.
Thereafter, cells were fixed, permeabilized, and
stained with the PE-conjugated a-pSYK (pY352 or
pY348), PE-conjugated a-pBLNK (pY84) (BD Bio-
sciences) or isotype control antibodies. Flow cyto-
metric analysis was performed using a FACS Can-
to II flow cytometer (BD Biosciences).
DLBCL viable tumor cell suspensions
Using an institutional review board-approved
protocol, freshly obtained nodal primary DLBCL
specimens were minced over a wire mesh screen,
washed, filtered and centrifuged over Ficoll Hy-
paque (Isolymph; Gallard-Schlesinger Industries,
Garden City, NY) at 500 × g for 15 min. to isolate
viable mononuclear tumor cells. Thereafter, the
viable tumor cell suspensions were washed in
RPMI, resuspended in DMSO and cryopreserved
in liquid nitrogen. Prior to analysis, the tumor cell
suspensions were thawed and viable cells were iso-
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lated from a Ficoll Hypaque monolayer. The prima-
ry DLBCL tumor cell suspensions were analyzed
by intracellular phosphospecific flow cytometry for
pSYK (Y352) and pBLNK (pY84) at baseline, and
following anti-IgG/IgM crosslinking in the presence
or absence of R406, as described above.
Establishment of doxycycline-inducible
PTPROt cell lines
The PTPROt-inducible lymphoma cell line was
generated using a Tet-On Gene Expression System
(BD Biosciences Clontech, Palo Alto, CA). In brief,
the pTET-On regulatory plasmid was transfected
into the lymphoma cell line, and several independ-
ent G418-resistant clones (0.75 mg/ml) were ob-
tained. pTET-On–positive clones were screened for
low background and high inducibility with pTRE2-
-Luc. Thereafter, selected clones were stably trans-
fected with appropriate plasmids (pTRE2-PT-
-PROT-WT, pTRE2- PTPROT-C325S, or pTRE2-
-PTPROT-D291A) and selected with puromycin (at
1 µg/mL). The resulting transfectants were treat-
ed with doxycycline (1 µg/mL) for 12 hours at 37°C
to induce PTPROt expression.
Immunoprecipitation and immunoblotting
Cells were lysed in NP40 lysis buffer (1% NP-
-40, 50mM Tris-HCl [pH7.4], 150mM NaCl, and
2mM Na3VO4) containing protease inhibitors. Fol-
lowing centrifugation, supernatants were recovered
and used in immunoblotting or immunoprecipita-
tions. For immunoprecipitations, lysates were in-
cubated with 2 µg/mL a-SYK 4D10 or a-CD79a an-
tibody (Santa Cruz Biotechnology) at 4°C for 1 h
with rotation. Thereafter, 50 µL protein G–Sepha-
rose beads (50% slurry in lysis buffer) was added,
and samples were rotated for 1 additional hour.
Immunocomplexes were then recovered by cen-
trifugation, washed with cold lysis buffer, resus-
pended in sample buffer, boiled at 95°C for 10 min-
utes, size-fractionated by PAGE and transferred to
PVDF membranes (Millipore Corp., Bedford, MA).
Blots were first incubated in blocking buffer
(5% milk, 0.1% Tween in phosphate-buffered saline
[PBS]) for 30 minutes and subsequently incubated
1 hr at room temperature or overnight at 4°C (phos-
pho-specific or anti-pan-phospho-tyrosyl antibody).
After sequential washes with 0.1% Tween/PBS,
blots were incubated with horseradish peroxidase
(HRP)–labeled secondary antibodies at room tem-
perature for 1 hour, developed by enhanced chemi-
luminescence (Western Lighting Plus-ECL, Perk-
inElmer, Waltham, MA) and visualized with Kodak
Biomax film (Carestream Health, Inc., Rochester,
NY). To reprobe with another antibody, the blots
were stripped (0.063 M Tris-HCl [pH 6.8], 2% SDS,
0.026 M DTT) at 50°C for 30 minutes, washed and
analyzed with additional antibodies as indicated.
Antibodies used in immunoprecipitation and
immunoblotting included mouse monoclonal anti-
body anti-SYK, and anti-BLNK, rabbit polyclonal
antibody anti–extracellular signal–regulated kinase
1 (ERK1), (Santa Cruz Biotechnology, Santa Cruz,
CA), anti–phospho-p44/42mitogen-activated pro-
tein kinase (MAPK) antibody (Cell Signaling Tech-
nology, Danvers, MA), SYK Y352 [BD Bioscienc-
es, San Jose, CA], Y525/526, Y323 [Cell Signaling,
Danvers, MA], murine monoclonal anti–phospho-
BLNK (pY84), mouse monoclonal antiphosphotyro-
sine antibody (4G10; Upstate, Lake Placid, NY),
mouse monoclonal anti b-actin, and anti-FLAG an-
tibody (Sigma, St Louis, MO).
Quantitative chromatin
immunoprecipitation (QChIP)
Chromatin immunoprecipitations were per-
formed as previously described using Ramos, DHL4
or DHL6 cells [31, 37–40]. Briefly, cells were fixed
in 0.5% formaldehyde for 10 minutes at room tem-
perature. Reactions were subsequently quenched
in 0.2M glycine for 5 minutes. Cells were then washed
with 1X PBS and lysed in RIPA lysis buffer (150 mM
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris [pH 8.0], 2mM EDTA) contain-
ing protease inhibitors (Complete protease inhibi-
tor cocktail; Roche Applied Science) and sonicat-
ed. Lysates were precleared and subsequently in-
cubated with rabbit antisera directed against BCL6
(N3 antibody; Santa Cruz Biotechnology, Santa
Cruz, CA) or with normal rabbit IgG antibody (San-
ta Cruz Biotechnology). Immunocomplexes were
captured with protein A/G Plus agarose pre-blocked
with salmon sperm DNA (Abcam, Cambridge, MA)
and washed 3 times with RIPA buffer and once with
final ChiP wash buffer (1% NP40, 0.1% SDS,
500 mM NaCl , 2mM EDTA, pH 8.0, 20mM Tris-
-HCl, pH 8.0, with protease inhibitors). Thereafter,
immune complexes were eluted with 1% SDS in
100 mM NaHCO3 and crosslinks were reversed by
incubating samples for 4h at 65°C. Samples were then
digested with Proteinase K for 1h at 45°C. DNA
fragments enriched by ChIP were recovered by
standard phenol-chloroform extraction followed by
ethanol precipitation and quantified by real-time
PCR and PowerSYBR green kit (Applied Biosys-
tems, Foster City, CA). Relative enrichment in
BCL6 binding sites and control regions in BCL6-
-over control IgG-immunoprecipitated samples was
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calculated by using the 2-(DCT BCL6 - DCT IgG) method.
Standard deviations were calculated from triplicate
DDCT values. The known BCL6 binding sites in
the CCL3 and FCER2 genes [41, 42] were used
as positive controls for BCL6 target gene enrich-
ment while the CD20 gene, which is not a BCL6
target, was used as a negative control. Primers
used in these experiments are available upon
request.
ChIP on chip and data processing
After validation of enrichment by QPCR, BCL6
or actin ChIP products and their respective input
genomic fragments were amplified by ligation-
-mediated PCR (LMPCR) [43]. QChIP was repeat-
ed after amplification to verify that the enrichment
ratios were retained. The genomic products of three
biological ChIP replicates were labeled with Cy5
(for ChIP products) and Cy3 (for input) and co-
-hybridized on a NimbleGen human promoter array
representing 1.5 KB of promoter sequence from
24.275 genes (human genome v. 35, May 2004) ac-
cording to manufacturer’s protocol (NimbleGen
Systems, Madison, WI). The enrichment for each
promoter was calculated by computing the log-
-ratio between the probe intensities of the ChIP prod-
uct and input chromatin, which are co-hybridized on
the same array. Thereafter, for each of the 24,175
promoter regions, the maximum average log-ratio
of three neighboring probes in a sliding window was
calculated and compared with random permutation
of the log-ratios of all probes across the entire ar-
ray. The positive threshold was defined using the
CCL3 signal that corresponds to the 95th percentile
in random permutation of the log-ratios. The puta-
tive BCL6 binding regions were calculated from
triplicate experiments, represented as enrichment
peaks of BCL6 over control antibody signal and
aligned with chromosome positions (NCBI human
genome assembly v.35, May 2004). Thereafter,
using NimbleGen 24K promoter array annotation
file, the peak signals of BCL6 binding were assigned
to the respective regulatory regions of candidate
BCL6 target genes. In addition, all peaks were in-
spected using BLAT (The BLAST-like Alignment
Tool, http://genome.ucsc.edu) to identify genes on
opposite strand that could be regulated from the
same bidirectional promoter. Two genes were con-
sidered to be bidirectional partners when they were
located on the opposite strands in a “head-to-head”
orientation and their transcription start sites were
separated by less than 1kb [44]. In previous stud-
ies, 90% of promoters meeting these criteria were
bidirectionally active in functional assays [44, 45].
Gene Ontology Term Enrichment Analysis
 Gene Ontology (GO) term enrichment analy-
sis was performed with the online version of Gen-
eMerge program (http://www.oeb.harvard.edu/
/hartl/lab/publications/GeneMerge GeneMerge.html
[46]). Enrichment was assessed by comparing fre-
quency of GO Biological Process categories (http://
//www. geneontology.org/GO.doc.shtml) represent-
ed in the non-redundant list of SwissProt/TrEMBL
accession numbers of BCL6 target genes (n = 418)
versus the global frequency of GO categories in the
population gene file containing 19,168 non-redun-
dant SwissProt/TrEMBL accession numbers which
corresponded to known genes in NCBI human ge-
nome assembly v.36 (March 2006). SwissProt/
/TrEMBL IDs of remaining BCL6 target loci were
not available. All SwissProt/TrEMBL IDs were
obtained from the Affymetrix genome annotation
file supporting U133 Plus 2 GeneChip (ver. July
2006). Obtained p-values were corrected for multi-
ple hypothesis testing by FDR (False Discovery
Rate) [47, 48].
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) was
performed using the GSEA v1.0 program (availa-
ble from http://www.broad.mit.edu/gsea) [49], the
BCL6 target gene set and 2 independent series of
primary DLBCL with gene expression profiles and
consensus cluster and COO designations [9, 10].
Since the signature of the “HR” tumors is largely
defined by normal tumor-infiltrating host inflamma-
tory and immune cells, the analysis was focused on
“BCR” and “OxP” DLBCL. GSEA was performed
as previously described, with minor modifications.
The top 15,000 genes selected with a MAD-based
variation-filter were first ranked with respect to the
phenotype, “BCR” vs. “non-BCR”, using an abso-
lute value (rather than positive or negative) signal-
-to-noise ratio (SNR). With this approach, the final
position in the ranked gene list was only depend-
ent on the strength of the gene in discriminating
between phenotypes rather than specific up- or
down-regulation in a given phenotype. Represent-
ed members of the BCL6 target gene set were then
located within the ranked gene list and the proxim-
ity of the BCL6 target gene set to the most differ-
entially expressed “BCR” vs. “non-BCR” genes
(i.e., those with the highest absolute SNR value)
was measured with a weighted Kolmogorov-Smir-
nov statistic (ES, enrichment score [49]), with
a higher score corresponding to a higher proximi-
ty. The observed ES score was then compared to
the distribution of 1000 permuted ES scores (gene
50
Journal of Transfusion Medicine 2009, tom 2, nr 2
www.jtm.viamedica.pl
tag permutations) to assess statistical significance.
Similar results were observed with the permutation
of the class template (data not shown). The query
gene set included the 309 (out of total 485) BCL6
target genes present in the 15,000 ranked genes;
these 309 BCL6 targets were represented by 477
Affymetrix probe sets. BCL6 target gene enrich-
ment was also assessed in the gene list ranked for
the positively defined COO phenotypes “GC” vs.
“ABC” [9, 11] sorted by absolute SNRs.
GSEA was also performed in an independent
dataset of 218 primary DLBCL patients with avail-
able COO designations http://llmpp.nih.gov/
/DLBCL/DLBCL_patient_data_NEW.txt [10] and
consensus cluster assignments [9]. Affymetrix IDs
of BCL6 target genes were translated to Lympho-
chip IDs using current and archival UniGene clus-
ter IDs and used as the query gene set. Enrichment
was assessed as described above by ranking the
genes with respect to the absolute SNR values for
the comprehensive cluster phenotypes “BCR” vs.
“non-BCR” or COO phenotypes “GC” vs. “ABC”.
The top-scoring BCL6 target genes, described
as the “leading edge” genes, appear in the ranked
list at or before the point where the ES running sum
reaches its maximum deviation from zero [49]. The
leading-edge genes can be interpreted as the core
of a gene set that accounts for the enrichment sig-
nal [49]. These top-scoring BCL6 target genes were
clustered with respect to the “BCR” vs. “non-BCR”
tumor phenotypes and represented on heat maps
using the dChip 2006 program. For comparison, the
heat maps also included normal CD19+ sIgD- CD38+
GC B cells that were isolated as previously de-
scribed [50] and transcriptionally profiled at the
same time as the primary DLBCL [9].
GSEA in cell lines
Total RNA was extracted from a panel of
DLBCL cell lines, processed, hybridized to U133A
and B Affymetrix oligonucleotide microarrays,
scanned and analyzed as previously described [9].
Cell lines were then assigned to consensus clusters
using an ensemble classifier incorporating multiple
independent predictors as described above. Cell
lines that were assigned to “BCR” or “non-BCR”
categories with the highest probability were select-
ed for GSEA and additional functional analyses.
GSEA was performed as described above, using the
top 12,666 genes that met threshold and variation
index criteria [45]; genes were ranked according to
the absolute SNR values for the phenotype “BCR”
vs. “non-BCR”. The proximity of the BCL6 target
gene set to the top of the ranked list was measured
with an ES and the significance of the ES was de-
termined using 1000 gene tag permutations, as de-
scribed above.
Treatment with BCL6 inhibitory peptide
Peptides, including BCL6 inhibitory peptide
(BPI) and control were obtained from Bio-Synthe-
sis Inc. (Lewisville, TX) and stored at –20oC until
reconstituted with sterile pure water immediately
before use [32]. BPI purity was determined by
HPLC-MS to be 98% or higher. 25 × 104 DLBCL
cells were exposed to BPI or control peptide (0, 1,
2.5, 5, 10, 20, 40 and 80 µM) every 24 hrs. for 48
hrs. Cellular proliferation was assessed by MTT
assay as described above using 8 replicates per
treatment condition. The proliferation of BPI-treat-
ed cells (T) was normalized to their respective con-
trols (C) as follows: (T/C)corr (%) = (T/C) / UT × 100.
The growth inhibition (IC50) values were estimat-
ed by a linear least-squares regression of the (T/C)corr
values versus the concentration of BPI (or control)
peptide; T/Ccorr values of 50% were extrapolated.
The difference in BPI IC50s of “BCR” and “non-
-BCR” cell lines was assessed with a two-sided Stu-
dent t-test.
BCL6 target gene expression
After treatment with 20 mM of BPI or control
peptide for 8 hours, RNA was extracted from 104
DLBCL cells, using the RNeasy kit (Qiagen, Valen-
cia, CA). cDNA was synthesized using Superscript
III First Strand cDNA Synthesis kit (Invitrogen,
Carlsbad, CA). The mRNA levels of SUB1, CBX3,
CR1, ZNF433, CCN1, MBD1, CD74, FCER2 and
HPRT (housekeeping control) were detected using
the SYBRgreen kit (Applied Biosystems) and an
Opticon Engine 2 thermal cycler (MJ Research).
Primer sequences for QPCR are available upon re-
quest. The CT values of the genes of interest were
normalized to HPRT (DCT). DCT values of the BPI-
-treated cells were expressed relative to control
peptide-treated cells using the DDCT method. The
fold change in expression of each gene in BPI-treat-
ed vs. control peptide-treated cells was determined
by the expression: 2-DDCT with DDCT +s and DDCT
–s where s is the standard deviation of the DDCT
value for triplicates. Results were represented as
fold expression with standard deviation.
Microarray analysis of BCL6 and PTPRO
in normal B cells and in tumor samples
Two previously described datasets of transcrip-
tionally profiled newly diagnosed DLBCL [9, 10] and
an additional series of profiled normal B-cell sub-
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sets (naïve, centroblasts, centrocytes, and memo-
ry cells) [51] were used to assess BCL6 and
PTPROt transcript abundance. An additional series
of highly purified normal B-cell subsets (naïve, cen-
troblasts, centrocytes, and memory cells) was iso-
lated from normal human tonsils by magnetic cell
separation (MidiMACS system, Miltenyi Biotec, Au-
burn, CA) and profiled using the Affymetrix
U133Plus platform as previously described [52]. Af-
fymetrix probes 208121_s_at (PTPRO), 203140_at,
215990_s_at (BCL6) and dChip 2007 program were
used to assess PTPROt and BCL6 transcript abun-
dance in the Monti et al. [9] dataset; for lympho-
chip [10] dataset, the following probes were used:
17772 (PTPRO), 26535, 24429, 19268 (BCL6).
Computational analysis of PTPROt
promoter, generation of PTPROt
promoter constructs and luciferase assays
Computational analysis of PTPROt promoter
was performed with the publicly available MatIn-
spector module of Genomatix suite (http://
//www.genomatix.de). The ~1.6 kb sequence span-
ning –1.1 kb upstream to +0.5 kb downstream from
previously identified PTPROt transcription start
site (TSS) [50] was interrogated and three putative
BCL6 binding sites were identified. To generate
a PTPROt promoter reporter construct, a fragment
spanning nucleotides –1108 to +381 was PCR-am-
plified and cloned into the promoterless pGL3 luci-
ferase vector (Promega, Madison, WI). Deletions
in BCL6 binding sites were generated using the
GeneTailor Site-Directed Mutagenesis System (In-
vitrogen, Carlsbad, CA) as recommended by the
manufacturer. BCL6 constructs encoding either the
wild type protein (pMT2T-HA-BCL6) or mutant pro-
tein, lacking N-terminal POZ domain or C-terminal
zinc fingers, (pMT2T-HA-BCL6-ZF and pMT2T-
-HA-BCL6-DZF, respectively) were utilized [37].
For luciferase assays, HEK293T cells were
maintained in Dulbecco-modified Eagle’s medium
(Cellgro Mediatech, Herndon, VA) supplemented
with 10% fetal calf serum (Cellgro Mediatech), 10 mM
HEPES buffer, 4 mM L-glutamine, 50 U/mL peni-
cillin and 50 U/mL streptomycin. HEK293T cells
were seeded on 6 well-plates, grown to 60–80%
confluency and cotransfected with 350 ng/well of the
appropriate promoter pGL3 construct (wild-type or
mutant PTPROt promoter construct), 150 ng/well
of the control reporter plasmid, pRL-TK (Prome-
ga) and 5–100 ng of wild-type or mutant BCL6 con-
struct using FuGENE 6 transfection reagent (Ro-
che Applied Science, Indianapolis, IN) according to
manufacturer’s protocol. After 24 h of incubation,
cells were lysed and luciferase activities were de-
termined by chemoluminescence assay using the
Dual Luciferase Assay kit (Promega) and Lumi-
noskan Ascent luminometer (Thermo Lab Systems,
Franklin, MA). Luciferase activities are presented
as means from 3 experiments ± SD.
Analysis of BCL6-mediated PTPROt
repression in normal tonsillar naïve
B-cells and centroblasts
Normal naïve B-cells and centroblasts were
obtained from human tonsils by magnetic cell sepa-
ration with the MidiMACS system (Miltenyi Bio-
tec) as previously described [52]. Expression of the
BCL6 construct in naive B cells was achieved by
infection of the cells with a FUGW lentivirus vector
(Addgene, Cambridge, MA) expressing BCL6 or an
EGFP-only control as previously described [52]. For
BCL6 knockdown in centroblasts, BCL6-specific or
a negative control ”scrambled” shRNA cloned into the
pFIV-H1-copGFP vector were used [50].Following
48h, total RNA was prepared with TRIzol (Invitrogen)
and reverse-transcribed to cDNA with the Super-
script III first-strand cDNA synthesis kit (Invitro-
gen). PTPROt transcript abundance was evaluated
by quantitative 5’-nuclease assay PCR with the fol-
lowing primers and 5’-FAM labeled MGB probe:
Forward: ACTTTGTCTTTGCTCAGAACCAG;
Reverse: AGAAACAGCAACTGGTTCCTGAAG;
probe: CACTCTTCGCAGTGAAC. PCR was per-
formed using an ABI 7700 thermal cycler (Applied
Biosystems) and threshold cycle (CT) values were
generated using the Sequence Detection Software,
version 1.2 (Applied Biosystems). PTPROt tran-
script abundance was calculated relative to the
housekeeping control cyclophilin A (Applied Bio-
systems, cat. no 4326316E) using the 2-(DCT PTPROt - DCT
PPIA1) method. Standard deviations were calculated
from triplicate DDCT values. For absolute mRNA
copy number quantification, PCR was performed
with a serial dilutions of plasmid DNA containing
the PCR target sequence. CT values from the seri-
al dilutions were plotted against log (# plasmid cop-
ies) to generate standard curves as described pre-
viously [45]. Expression of the control BCL6 tar-
get gene, FCER2, was assessed relative to GAPDH
by using RT-PCR, PowerSYBR Green kit and the
following primers: FCER2, F: ATGAATCCTC-
CAAGCAGGAG, FCER2, R: GACTTGAAGCT-
GCTCAGACTGCT; GAPDH, F: GATTCCAC-
CCATGGCAAATTC; GAPDH, R: TGATTTT-
GGAGGGATCTCGCTC.
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RNA-interference mediated
BCL6 knock-down
BCL6-specific onTARGET plus siRNA and
negative control scrambled oligo (CCUCCAUAU-
CUCGCGCGUCUU) were obtained form Thermo
Scientific (Thermo Scientific, Waltham, MA). Oli-
gos were resuspended in RNAse-free water at 50
mM and stored at –70°C. For siRNA nucleofections,
4 x 106 of DHL4 cells were resuspended in 100 mL
of AMAXA nucleofector solution V containing 75
pmoles of BCL6 or SCR oligo and treated with O–017
program in Nucleofector II device (AMAXA, Koeln,
Germany). Transduction efficiency was confirmed
to be above 90% by nucleofection of Cy3-labeled
GAPDH oligo (Applied Biosystems/Ambion, Aus-
tin, TX) and subsequent flow cytometry analysis.
After nucleofections, DHL4 cells were incubated for
72h and used for phospho-specific flow cytometry,
or to prepare whole-cell extracts (WCE) for immu-
nobloting or for immunoprecipitations.
Immunoblot analysis of SYK
and BLNK phosphorylations
following BCL6 knockdown
Whole–cell extracts from BCL6 siRNA-trans-
duced cells were obtained by directly lysing cells
in the RIPA lysis buffer. For immunoprecipitations,
cells were first resuspended in 150 mL of PBS con-
taining 1% FCS and left untreated or stimulated
with goat anti–human IgG at 37°C for 1 minute as
described above. Cell suspensions were immediate-
ly lysed in 150mL of 2x NP40 lysis buffer (2% NP-
40, 100 mM Tris-HCl [pH7.4], 300 mM NaCl, 4 mM
Na3VO4 with protease inhibitors) and immunopre-
cipitations with a-SYK were performed as described
above. Lysates or immunoprecipitates were size-
fractionated on NuPAGE Novex 4–12% Bis-Tris
Gels (Invitrogen), and transferred to PVDF mem-
branes (Millipore). Blots were incubated with pri-
mary antibodies, washed, incubated with appropri-
ate HRP–labeled secondary antibodies, developed
and visualized as described above.
Results
1. Constitutive SYK-dependent tonic B-cell
receptor signaling is a survival pathway in
the “BCR” molecular type of diffuse large
B-cell lymphomas
1.1. An ATP-competitive, specific inhibitor
of SYK (R406) inhibits proliferation and indu-
ces apoptosis of “BCR”-type DLBCL cell lines
To investigate the postulated pro-survival role
of tonic BCR signaling in DLBCL, the effect of the
SYK inhibitor (R406) on the cellular proliferation
of a large panel of DLBCL cell lines was assessed.
These DLBCL were treated with serial dilutions of
R406 or vehicle alone and proliferation was evalu-
ated thereafter by MTT assay. In the majority of
the DLBCL cell lines, R406 inhibited cellular pro-
liferation at IC50s ranging from 0.8 µM to 8.1 µM
(data not shown and [33]). R406 cytotoxicity to
DLBCL was next evaluated using 2 doses of the
SYK inhibitor, 1 µM and 4 µM, derived from the
IC50 analysis. The DLBCL were cultured with R406
or vehicle alone and assessed for apoptosis by an-
nexin V–FITC/propidium iodide (PI) staining. Ten
of the DLBCL cell lines exhibited high levels of
apoptosis following R406 treatment (Figure 1, left
panel), whereas 5 lines did not undergo R406-as-
sociated apoptosis (Figure 1, right panel). Of inter-
est, all of the R406-sensitive cell lines were previ-
ously designated “BCR-type” DLBCL using the cell
line transcriptional profiles and a recently described
ensemble classifier [33, 34] (Figure 1, left panel).
In contrast, none of the R406-insensitive cell lines
were identified as “BCR-type” tumors (Figure 1,
right panel). Taken together, these data suggest
that transcriptional profile-defined “BCR-type”
DLBCL may be uniquely reliant on BCR-mediated
survival signals.
1.2. “BCR” type cell lines exhibit tonic BCR
activity that can be specifically inhibited
with R406
SYK activation requires LYN-mediated phos-
phorylation of SYK Y352 and Y348 in the linker re-
gion followed by autophosphorylation of SYK Y525/
/526 in the catalytic domain (Figure 2A). Subse-
quent phosphorylation of SYK Y323 leads to Cbl-
mediated ubiquitylation and degradation of SYK.
Given the critical role of SYK in low-level tonic BCR
signaling, a highly sensitive, recently described
method of single-cell phospho-flow cytometry was
used to assess SYK phosphorylation and signaling
in the DLBCL cell lines in the absence of BCR
crosslinking [36, 53]. With this approach, it is pos-
sible to precisely quantitate SYK activation by
measuring phospho-SYK348, -SYK352, and -BLNK
expression in DLBCL before and after BCR engage-
ment (Figure 2). Of interest, all of the “BCR-type”
DLBCL cell lines exhibited immunodetectable tonic
phosphorylation of SYK348 and SYK352 and the ma-
jority of these lines also had lower but detectable
baseline phospho-BLNK (Figure 2B). As expected,
SYK348, SYK352, and BLNK phosphorylation
markedly increased following BCR crosslinking in
these DLBCL (Figure 2B). Only 2 of 5 “non-BCR”
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DLBCL cell lines exhibited tonic phosphorylation
of SYK348 and SYK352 and none of these lines had
evidence of tonic phospho-BLNK (Figure 2C). Af-
ter documenting SYK and BLNK phosphorylation
in R406-sensitive DLBCL in the absence of Ig
crosslinking, the effects of R406 on tonic BCR sig-
naling was assessed. Since R406 specifically inhib-
its SYK525/526 autophosphorylation and down-
stream signaling events including the phosphoryla-
tion of BLNK [33], R406-sensitive DLBCL cell lines
were treated with R406 or vehicle alone, and tonic
pBLNK levels were evaluated in the absence of Ig
crosslinking (Figure 3). As indicated, R406 treat-
ment markedly reduced tonic BLNK phosphoryla-
tion (Figure 3).
1.3. R406 inhibits BCR signaling
in a subset of primary DLBCL
After demonstrating that R406 sensitivity was
dependent on intact BCR signaling in DLBCL cell
lines, the same parameters were evaluated in via-
ble tumor cell suspensions from 10 primary
DLBCL. Prior to these experiments, surface Ig iso-
type was determined by flow cytometry (data not
shown and [33]) and subsequently, pSYK352 and
pBLNK expression at baseline and following BCR
crosslinking were compared in the presence or ab-
sence of R406. Five representative primary DLB-
CL are shown in Figure 4. In the majority of exam-
ined primary DLBCL, the tumor cells expressed
clearly detectable pSYK352 at baseline (Figure 4A,
top panel). In each of these viable tumor cell sam-
ples, BCR crosslinking markedly increased SYK352
and BLNK tyrosyl phosphorylation (Figure 4A, top
panel). Furthermore, R406 inhibited the SYK-de-
pendent phosphorylation of BLNK following BCR
engagement (Figure 4A, bottom panel). In marked
contrast, other primary DLBCL had no or low levels
of detectable pSYK352 at baseline (Figure 4B, top
panel). In these primary DLBCL, there was no change
in pSYK352 and pBLNK levels following BCR
crosslinking (Figure 4B, top panel) and R406 had no
observed effect (Figure 4B, bottom panel). These
analyses of primary DLBCL which are in agreement
with those of DLBCL cell lines (Figures 2–3), indi-
cate that primary DLBCL also differ in their tonic
and induced BCR signaling and sensitivity to R406.
2. Identification of the phosphatase
— dependent mechanism controlling
SYK activity
Consistent with the central role of SYK in reg-
ulating tonic and ligand-dependent BCR signaling,
SYK activity is tightly regulated by BCR-associat-
ed phosphorylation, Cbl-mediated proteasomal deg-
radation and PTP activity. Pilot studies suggested
that SYK activity could be controlled by a tissue-
specific and developmentally regulated PTP,
PTPROt (Protein Tyrosine Phosphatase Receptor
Type O, truncated) [54]. PTPROt coimmunoprecip-
itaded with SYK, indicating that these proteins form
a complex. In addition, the substrate-trapping mu-
tants of PTPROt that lack catalytic activity, but re-
tain the ability to bind substrates, bound significant-
ly more tyrosyl-phosphorylated and total SYK than
wild-type PTPROt (PTPROt-WT), suggesting that
SYK could be a PTPROt substrate in vivo.
2.1. Characterization of PTPROt role
in dephosphorylating SYK Y352 in vivo
To furher characterize PTPROt substrates in
vivo, tet-inducible B-cell lines that expressed either
WT or CS mutant FLAG-tagged PTPROt were
used. If SYK is a PTPROt substrate, overexpres-
sion of WT PTPROt would inhibit BCR-triggered
SYK tyrosyl phosphorylation. SYK activation re-
quires LYN-mediated phosphorylation of SYK Y352
and Y348 in the linker region followed by autophos-
phorylation of SYK Y525/526 in the catalytic domain
(Figure 2A). Subsequent phosphorylation of SYK
Y323 leads to Cbl-mediated ubiquitylation and deg-
radation of SYK. To confirm that SYK is a PTPROt
substrate and identify specific PTPROt SYK tyro-
sine substrate, Flag-tagged WT or CS mutant PT-
PROt were overexpressed in DLBCL cells, BCR
was crosslinked for 5 min and BCR-induced phos-
phorylation at SYK Y352, Y525/526 and Y323 were
compared (Figure 5A). At this early timepoint, SYK
Y352 phosphorylation was specifically inhibited by
overexpression of WT-PTPROt, but not by the in-
active CS-PTPROt mutant (Figure 5A). In the same
experiments, WT-PTPROt overexpression did not
alter the phosphorylation of upstream BCR pathway
components such as CD79a (Iga) (Figure 5A, bot-
tom panel). To assess the effects of PTPROt on the
subsequent phosphorylation of SYK Y525/526 and
Y323, the same experiments following 15 minutes
of BCR crosslinking were performed (Figure 5B).
At this later timepoint, when phosphorylation of
all three SYK tyrosine residues is detectable,
overexpression of WT-PTPROt, but not CS-PT-
PROt, inhibited phosphorylation of SYK Y352,
Y525/526 and Y323 (Figure 5B). Taken together,
these results indicate that PTPROt dephosphor-
ylates SYK Y352, limiting subsequent SYK Y525/526
autophosphorylation and activation of the BCR
pathway.
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2.2. PTPROt overexpression inhibits SYK-
-dependent MAPK/ERK signaling, cellular
proliferation and induces apoptosis
Given the central role of SYK in transducing,
amplifying and propagating the original signal to the
downstream components of the BCR signaling path-
way, it was likely that PTPROt overexpression
would alter the phosphorylation of downstream SYK
targets and associated cellular proliferation. Since
the MAPK/ERK signaling pathway is one of the
most important downstream signaling pathways
regulated by SYK [55, 56], the phosphorylation of
ERK1/2 in Dox-induced PTPROt-WT and mutant
transfectants was investigated. ERK1/2 was strongly
phosphorylated after BCR cross-linking (Figure 6,
lane 2), and ERK1/2 phosphorylation was signifi-
cantly inhibited by PTPROt-WT overexpression
(Figure 6; compare lanes 2 and 4). In contrast, over-
expression of PTPROt-CS or -DA mutants had lit-
tle effect on ERK1/2 phosphorylation (Figure 6,
lanes 8 and 12). Given the role of the MAPK/ERK
signaling pathway in regulating cellular prolifera-
tion [57], the effect of PTPROt overexpression on
cell growth using an MTT assay was next examined.
Cellular proliferation was completely inhibited
when PTPROt-WT transfectants were induced with
Dox, although these cells grew normally in the ab-
sence of Dox (and PTPROt-WT expression) (Fig-
ure 7A, left panel). In marked contrast, cellular pro-
liferation was not significantly altered by the induc-
tion of either PTPROt mutant (DA, CS) (Figure 7A,
middle and right panels). In companion experi-
ments, the effect of PTPROt overexpression on
cellular apoptosis was assessed with annexin
V–FITC/PI staining. Dox-induced PTPROt-WT dra-
matically increased the apoptotic cell fraction,
whereas neither PTPROt mutant (DA or CS) had
this effect (Figure 7B; compare left vs. middle/right
panels).
3. Identification of BCL6-dependent,
functional signature of “BCR” type
DLBCL
The first part of studies demonstrated that that
the molecular signature of “BCR”-type DLBCL has
strong biological foundations in constitutive tonic
BCR activity that is controlled by the PTPROt ac-
tivity and therapeutically targetable. As the “BCR”
molecular signature includes increased expression
of BCL6, it was likely that deregulated expression
of this proto-oncogene would have similar biologi-
cal imprint. Specifically, these characteristics
prompted speculations that “BCR” tumors would
have a transcriptional signature that was defined,
at least in part, by the differential expression of
BCL6 target genes, and be more likely to rely upon
deregulated BCL6 expression and be uniquely sen-
sitive to BCL6 inhibition.
3.1. Identification and functional
characterization of BCL6 target genes
To investigate these hypotheses, a comprehen-
sive, BCL6-driven genetic signature was required.
To identify BCL6 target genes, high throughput
chromatin immunoprecipitation (ChIP on chip) was
performed. Ramos B-cell lymphoma cell line which
is frequently used to evaluate BCL6 function was
utilized for these experiments [37–39]. Chromatin
fragments were immunoprecipitated with an anti-
body directed against BCL6 or an irrelevant con-
trol. Thereafter, the resulting amplicons were la-
beled and co-hybridized with input chromatin to
high-density oligonucleotide arrays containing 1.5
KB sequence of 24,275 gene promoters. “Hits”
were captured through a highly stringent approach
employing random permutation analysis on a slid-
ing window of oligonucleotide probes (i.e. on groups
of three consecutive probes). The threshold of pos-
itivity was set at the enrichment level of the known
BCL6 binding site in the CCL3 promoter [41],
which corresponded to the 95th percentile confi-
dence interval for this method. Only genes that
were captured by all three replicates and that dis-
played overlapping peak enrichment were consid-
ered positive.
BCL6 was recruited to 436 promoters, poten-
tially regulating 485 target genes, including known
target genes such as FCER2 and CCL3 [41, 42]
(The complete list of genes is available at the fol-
lowing URL: http://www.pnas.org/content/suppl/
/2007/02/13/ 0611399104.DC1/11399Table_2.pdf)
To determine the accuracy of BCL6 target gene
discovery, single locus quantitative ChIP was per-
formed on 54 of the candidate BCL6 target genes
using the known targets CCL3 and FCER2 as posi-
tive controls. Eighty-one percent of the examined
candidate BCL6 target genes were confirmed with
this stringent approach (Figure 8).
To gain insights into the functions of identified
BCL6 target genes, their associated GO Biological
Process terms were evaluated. GO terms annotate
genes and their products based on described bio-
logical functions. Specifically, the representation of
GO terms in the BCL6 target gene set with that in
the total analyzed gene pool (i.e. all the genes in the
GO database) was compared [46]. The BCL6 target
gene list was enriched in genes regulating transcrip-
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tion, DNA damage responses, chromatin modifica-
tion, cell cycle and protein ubiquitylation (Table 1).
3.2. Differential BCL6 target gene
expression in DLBCL subtypes
It could be predicted that differential expres-
sion of BCL6 target genes would identify DLBCL
in which BCL6 plays a dominant oncogenic role and
assessed the relative abundance of BCL6 targets in
the respective DLBCL consensus clusters [9]. In
this analysis, gene set enrichment analysis (GSEA)
was used to determine whether the set of BCL6
target genes was differentially expressed in a spe-
cific DLBCL subtype [49]. Although BCL6 likely
functions as a direct transcriptional repressor,
the absolute levels of specific target genes may de-
pend upon BCL6 cooperation with other transcrip-
tion factors, binding to different co-repressors, or
additional epigenetic modifications of chromatin.
For these reasons, phenotype ranking was per-
formed according to absolute (rather than positive
or negative) signal to noise ratios (SNR) and the en-
richment of BCL6 target genes in the ranked data-
set was assessed. In the series of 176 primary
DLBCL, the “BCR” vs. “non-BCR” ranked gene list
was significantly enriched for BCL6 target genes
(p < .0001), indicating that the BCL6 signature con-
tributes to the difference between “BCR” and “non-
BCR” tumors.
To validate these observations in an independ-
ent dataset, GSEA was performed in an additional
large series of transcriptionally profiled primary
DLBCL with available COO and consensus cluster
designations [9, 10]. In this independent series,
BCL6 targets were similarly enriched in ranked
genes discriminating between “BCR” and “non-
-BCR” signatures (p = 0.017). In contrast, BCL6
target genes were not significantly enriched in ei-
ther dataset when the DLBCL were sorted with
respect to the “GCB” vs. “ABC” classification.
To determine which BCL6 targets were more
(or less) abundant in “BCR” vs. “non-BCR”
DLBCL, the BCL6 target genes were clustered with
respect to these tumor types. The top-scoring
BCL6 target genes (“the leading edge” [see Meth-
ods] [49]) were represented on a heat map that in-
cluded normal tonsillar GC B cells for comparison
(Figure 9A). Consistent with the known role of
BCL6 as a transcriptional repressor, a number of
BCL6 target transcripts were less abundant in
“BCR” DLBCL than in “non-BCR” tumors (Figure
9A); the majority of these BCL6 targets were also
less abundant in normal GC B cells (Figure 9A).
However, additional bona fide BCL6 targets were
more abundant in “BCR” tumors and normal GC B
cells than “non-BCR” DLBCL (Figure 9A). To ex-
plain this unexpected observation, the BCL6 de-
pendence of candidate target genes in a panel of
informative DLBCL cell lines was analyzed.
3.3. BCL6 actively represses its target genes
in “BCR” but not in “non-BCR” tumors
For these analyses, representative “BCR” or
“non-BCR” DLBCL cell lines (“BCR” — Ly1, Ly7,
SU-DHL4, SU-DHL6 and Farage; and “non-BCR”
— Ly4, Toledo, Karpas 422 and Pfeiffer) were used.
The above phenotype assignment was based on the
cell transcriptional profiles and an “ensemble clas-
sifier” (see Materials and Methods). Thereafter,
GSEA was performed for BCL6 targets using the
cell line gene list, ranked according to absolute SNR
values for the “BCR” vs. “non-BCR” distinction. As
was the case in primary DLBCL, BCL6 target genes
were highly enriched in the ranked cell line gene
Table 1. Gene Ontology (GO) term analysis of BCL6 target genes
GO Term GO term frequency Global GO term frequency P value FDR
in BCL6 target
gene set
Transcription 37/418 (0.0885) 0.0386 0.0000 0.0003
Protein ubiquitination 15/418 (0.0359) 0.0096 0.0000 0.0006
Cell cycle 14/418 (0.0335) 0.0103 0.0001 0.0035
Ubiquitin cycle 12/418 (0.0287) 0.0083 0.0002 0.0043
Chromatin modification 6/418 (0.0144) 0.0023 0.0003 0.0053
Response to DNA damage stimulus 3/418 (0.0072) 0.0004 0.0004 0.0053
Regulation of transcription, 41/418 (0.0981) 0.0567 0.0005 0.006
DNA-dependent
Ubiquitin-dependent protein catabolism 7/418 (0.0167) 0.0039 0.0011 0.013
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list (p < .001). In addition, certain BCL6 target tran-
scripts were less abundant in “BCR” than in “non-
-BCR” cell lines whereas other BCL6 targets were
more abundant in “BCR” DLBCL (Figure 9B).
Then, the panel of four “BCR” and “non-BCR”
cell lines was treated with BPI and the transcript
abundance of representative BCL6 targets was val-
uated (Figure 9C). The BCL6 targets chosen for this
analysis were: (1) validated by Q-ChIP; (2) includ-
ed in a significantly enriched GO category; and (3)
most differentially expressed in “BCR” and “non-
BCR” tumors (i.e. included in the leading edge gene
set). Specifically, selected genes included certain
candidate BCL6 targets that were less abundant in
“BCR” than in “non-BCR” cells (SUB1, ZNF443,
CR1, CBX3) at baseline (shaded in blue in Figure
9C), and others that were more abundant in “BCR”
tumors (CD74, CCN1, MBD1, FCER2) (shaded in
red in Figure 9C). BPI treatment increased the
expression of each of these BCL6 targets in the
“BCR” DLBCL cell lines but did not alter the ex-
pression of these genes in “non-BCR” tumors (Fig-
ure 9C). These data suggest that BCL6 is biologi-
cally active in “BCR”, but not in “non-BCR”, tumors
and show that BCL6 represses its target genes in
“BCR” DLBCL regardless of their baseline levels.
3.4. Disruption of the BCL6 transcriptional
program selectively inhibits proliferation
of “BCR”-type DLBCL cell lines
Since BPI selectively increased BCL6 target
expression in “BCR” DLBCL, it could be predict-
ed that these tumors would be more dependent on
BCL6-regulated gene pathways than “non-BCR”
DLBCL. It had been previously shown that BPI
specifically blocked BCL6 activities in vitro and in
vivo and inhibited the growth of certain BCL6-pos-
itive lymphomas [31]. For this reason, the 5 “BCR”
and 4 “non-BCR” DLBCL cell lines were treated
with BPI and tumor cell proliferation was subse-
quently evaluated. In these experiments, cell line
identity was blinded until after the functional data
were independently analyzed.
“BCR” cell lines had significantly lower BPI
IC50s than “non-BCR” lines, which were uniform-
ly resistant to the peptide inhibitor (“BCR” vs.
“non-BCR” DLBCL IC50, 12.7 + 3.49 mM vs. 50.15
+ 4.43 mM, p < .0001, Figure 10 A & B). To fur-
ther characterize the differential sensitivity of
“BCR” vs. “non-BCR” cell lines, the panel was ex-
posed to 20 mM BPI for 48 hrs. BPI inhibited cel-
lular proliferation of “BCR” DLBCL cell lines by
65–90% but had little effect on “non-BCR” tumors
(Figure 10C).
4. Characterization of BCL6 role
in tonic BCR signaling in DLBCL
Since the same transcriptionally defined sub-
set of DLBCL relies upon SYK-dependent BCR sig-
naling and exhibits coordinate BCL6-mediated tran-
scriptional repression, the relationship between
these two processes was explored.
4.1. Reciprocal patterns of PTPROt and
BCL6 expression in normal B cells and
primary DLBCL
To identify putative BCL6 target genes in-
volved in BCR signaling, the relative expression of
multiple proximal components of BCR signaling
cascade and BCL6 was first compared. PTPROt and
BCL6 exhibited reciprocal expression pattern in 2
independent series of highly purified naïve, GC and
memory B cells analyzed by transcriptional profil-
ing (Figure 11A). Consistent with BCL6 transcrip-
tional repressor function, PTPROt transcripts were
significantly more abundant in normal naïve and
memory B cells than in GC B cells whereas BCL6
expression was highest in normal GC B cells (Fig-
ure 11A). In addition, there were reciprocal patterns
of BCL6 and PTPROt expression in 2 large inde-
pendent series of primary DLBCL (Figure 11B). Of
note, over 78% of primary DLBCL with high BCL6
and low PTPROt transcript levels were previously
identified as “BCR-type” tumors (Figure 11B, Chi-
square test, p < .001).
4.2. PTPROt is a BCL6 target gene
The reciprocal patterns of BCL6 and PTPROt
expression in normal B cells and primary DLBCL
and the identification of BCL6-high/PTPROt-low
“BCR-type” DLBCL raised the possibility that
PTPROt was a target gene of BCL6. To investigate
this postulated relationship, a bioinformatic analy-
sis of PTPROt promoter was performed. Specifical-
ly, the presence of a structural BCL6-binding motif
was sought. The 1.5 kb PTPROt promoter region,
which encompassed the previously identified tran-
scription start site (TSS) and TATA box [50, 58],
included 3 candidate BCL6 binding sites (–763 to
–746; –124 to –107; +300 to +317 nt from TSS).
Of note, the two upstream candidate BCL6 binding
sites (–763 to –746 and –124 to –107) are located
within a region of the PTPROt promoter associat-
ed with repressed basal transcriptional activity [58].
To assess the functional status of the candidate
BCL6 binding sites, a luciferase vector driven by
the PTPROt promoter (pGL3-Luc-PTPROt-
-1108+381) was generated. This PTPROt-luciferase
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construct was cotransfected into HEK293T cells
with a vector encoding either wild-type BCL6 or
one of two inactive BCL6 mutants, BCL6-ZF or
BCL6-DZF (lacking the amino-terminal transcrip-
tional repressor domain or carboxy-terminal DNA
binding zinc-finger sequence, respectively). WT
BCL6 repressed PTPROt-driven luciferase activi-
ty in a dose-dependent manner (Figure 12A); in
marked contrast, neither of the inactive BCL6 mu-
tants decreased expression of the PTPROt report-
er gene (Figure 12B).
To investigate whether endogenous BCL6
binds the PTPROt promoter region in vivo, a chro-
matin immunoprecipitation assay was utilized. In
two “BCR-type” DLBCL cell lines (DHL4 and
DHL6), DNA fragments including the predicted
BCL6 binding sites, but not two upstream/down-
stream control fragments, were significantly enri-
ched in a-BCL6 chromatin immunoprecipitates (Fi-
gure 13A). These data suggest that each of the iden-
tified binding sites is occupied by BCL6 in vivo
(Figure 13A). Consistent with these observations,
individual mutations of each of the predicted BCL6
binding sites decreased BCL6-mediated repression
of PTPROt and combined mutations of all 3 BCL6
binding sites in PTPROt promoter abolished its
response to BCL6 (Figure 13B). Taken together,
these results indicate that BCL6 represses the ac-
tivity of the PTPROt promoter and that this func-
tion requires the identified BCL6 binding sites.
4.3. BCL6 regulates PTPROt expression
in normal B cells and DLBCL
Given the reciprocal, developmentally regula-
ted pattern of expression of BCL6 and PTPROt in
normal B cells, it was of interest whether PTPROt
is a physiological target of BCL6 in highly purified
naïve B-cells and GC centroblasts. After transdu-
cing naïve B cells with a BCL6 lentiviral vector and
centroblasts with a BCL6-shRNA construct,
PTPROt expression was assessed by RT PCR (Fi-
gure 14A). In naïve B cells, the forced overexpres-
sion of BCL6 markedly decreased PTPROt trans-
cript abundance (Figure 14A, left panel). Conver-
sely, BCL6 depletion increased PTPROt expression
in normal centroblasts (Figure 14A, right panel).
After demonstrating that PTPROt is a physio-
logical target of BCL6 in normal B-cells (Figure
14A), BCL6 role in modulation of PTPROt expres-
sion in a representative “BCR”-type DLBCL cell
line was assessed (Figure 14B). Under conditions
in which BCL6 siRNA increased the abundance of
known BCL6 target gene FCER2 (data not shown),
BCL6 depletion increased PTPROt transcript abun-
dance 10-fold (Figure 14A). Of note, BCL6 depletion
did not change the expression of total SYK, upstream
BCR pathway components such as CD79a or down-
stream adapter proteins such as BLNK. These data
indicate that BCL6 specifically modulates PTPROt
expression in normal B cells and certain DLBCL.
4.4. BCL6-mediated repression of PTPROt
increases SYK Y352 phosphorylation
and promotes BCR signaling
After demonstrating that PTPROt is a trans-
criptional target of BCL6, the consequences of
BCL6 depletion on SYK phosphorylation and tonic
BCR signaling in a representative “BCR”-type
DLBCL cell line (DHL4) were assessed. The
DLBCL line was transduced with BCL6-siRNA or
scrambled control; thereafter, cells were lysed,
immunoprecipitated with pan SYK antibody and
immunoblotted with an anti-phospho SYK Y352
antibody. SYK phosphorylation was markedly lower
in BCL6-depleted cells than in parental or mock-
transduced cells (Figure 15A). Next, single-cell
phospho-specific flow cytometry was used to spe-
cifically assess SYK Y352 phosphorylation and BCR
signaling following BCL6 knockdown. Tonic and
BCR crosslink-associated phosphorylation of SYK
Y352 was much lower in BCL6-depleted cells than
in control and parental cells (Figure 15B). Phospho-
rylation of the associated adaptor protein, BLNK,
was similarly decreased in BCL6-depleted, but not
in control or parental cells (Figure 15B). Taken to-
gether, these data confirm that BCL6 regulates to-
nic and BCR-crosslink-induced signaling of the BCR
pathway by repressing SYK phosphatase, PTPROt.
Discussion
The molecular characteristics of the “BCR”
DLBCL subtype defined by the comprehensive
genetic signature suggested that these tumors mi-
ght be reliant on BCR/SYK signaling pathway and
BCL6 transcriptional program. To investigate the-
se hypotheses, a comprehensive genetic, molecu-
lar and biochemical studies were performed to spe-
cifically assess the role of BCR/SYK-dependent si-
gnaling in “BCR”-type DLBCL and the biological
consequences of its inhibition in vitro, mechanisms
controlling SYK activity, role of transcriptional pro-
gram controlled by BCL6 and the biological conse-
quences of its inhibition in vitro, and relationship
between BCL6 mediated repression and SYK-de-
pendent signaling in “BCR”-type DLBCL.
Performed studies functionally characterized
the molecular signature of “BCR”-type DLBCL
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and identified BCR signaling and BCL6 transcrip-
tional program to be critical pro-survival mecha-
nisms in this DLBCL subtype. These findings have
direct translational consequences, since both pa-
thways are therapeutically targetable. In addition,
a novel mechanism controlling BCR activity via
BCL6 mediated repression of PTPROt was iden-
tified, demonstrating that both pathways are func-
tionally related and suggesting that a combined
inhibition could have synergistic effect in these
DLBCL.
1. Characterization of critical survival role
of tonic SYK-dependent BCR signaling
in “BCR” type DLBCL
The majority of examined DLBCL cell lines
exhibit tonic BCR signaling as evidenced by basal
phosphorylation of SYK348 and 352 and the SYK-
-dependent linker protein, BLNK. DLBCL cell lines
with an intact BCR signaling pathway were highly
sensitive to the ATP-competitive SYK inhibitor,
R406, which blocked downstream signaling and in-
duced apoptosis. Of interest, the DLBCL cell lines
with an intact BCR signaling pathway and sensiti-
vity to the SYK inhibitor were independently iden-
tified as “BCR” tumors on the basis of their trans-
criptional profiles. These data suggest that tonic
BCR signaling is an important and potentially tar-
getable survival pathway in these DLBCL and that
R406-sensitive DLBCL can be identified by their
transcriptional profiles. Of importance, tonic and
induced BCR signaling and R406 responses are
detectable in some, but not all, primary DLBCL,
indicating that the findings in DLBCL cell lines are
directly applicable to primary tumors and highligh-
ting the potential value of profile-defined compre-
hensive clusters [9] with targetable subtype-spe-
cific survival pathways. For all of these reasons,
SYK is an attractive rational target in DLBCL and
possibly other B-cell malignancies and R406 is
a promising targeted treatment. Safety and effica-
cy of the oral, single daily dose of R406 (FosD) in
patients with relapsed/refractory DLBCL (and other
lymphoid malignancies) was evaluated in a recen-
tly completed phase I/II clinical trial [59]. FosD was
very well tolerated and exhibited encouraging effi-
cacy in these patients. Response rate in relapsed
refractory DLBCL patients was 21%, 54% in small
lymphocytic/chronic lymphocytic leukemia (SLL/
/CLL), 10% in follicular lymphoma (FL), and 11% in
mantle cell lymphoma (MCL) [59]. Stable disease
was observed in an additional 23 patients, including
12 with FL, 4 with DLBCL, 4 with MCL, 2 with CLL/
/SLL and 1 with mucosa-associated lymphoid tis-
sue lymphoma [59]. Given the heavily pretreated
cohort of patients enrolled in this study and enco-
uraging results of FosD used as a single oral agent,
it can be expected that clinical applications of FosD
will be further developed, especially in rational com-
binations for BCR-dependent B-cell non-Hodgkin
lymphoma (NHL).
2. Mechanisms and regulation of tonic BCR
signaling in “BCR” tumors
Given the critical role of tonic BCR signaling
in normal B-cell development and lymphomagene-
sis, it could be expected that this process remains
under tight control. Tonic BCR signaling is thought
to be initiated and regulated by stochastic interac-
tions between PTKs and PTPs within cell membra-
ne lipid rafts. In this homeostatic equilibrium mo-
del [14], positive regulators transiently and stocha-
stically interact with the BCR complex and activate
receptor-associated PTKs, ITAM phosphorylation,
assembly of Ig/signaling complexes, and SYK pho-
sphorylation. This positive PTK-associated regula-
tory arm is counterbalanced by the recruitment of
negative regulators such as PTPROt. Inhibition of
the PTP-dependent negative-regulatory arm stabi-
lizes and enhances tonic BCR signals. The role of
PTPs in regulating tonic BCR signaling was first
suggested by studies in which BCR-proximal PTKs
were activated by treatment with the phosphatase
inhibitor, pervanadate/H2O2, in the absence of BCR
cross-linking [14, 15, 19, 20]. The current study
identifies PTPROt as a critical mechanism for en-
hanced SYK-dependent tonic BCR signaling.
PTPROt is a tissue-specific PTP that is expressed
and developmentally regulated in B lymphocytes. PT-
-PROt is a member of the PTPRO family (also desig-
nated GLEPP, PTP-f, PTP-OC and PTPu2), a group
of highly conserved receptor-type PTPs with a sin-
gle catalytic domain and transmembrane region and
a variably sized extracellular sequence [60, 61]. PT-
PRO includes an extended extracellular domain
whereas PTPROt contains a truncated extracellular
region. Initial studies suggested that PTPROt is
developmentally regulated and decreased in abun-
dance in normal germinal center B cells and a sub-
set of B-cell lymphomas [50]. In previous studies,
PTPROt overexpression markedly increased G0/G1
arrest, providing the first evidence that this PTP
regulated B-cell growth [50]. In the current study,
the overexpression of PTPROt inhibited BCR-trig-
gered SYK tyrosyl phosphorylation, activation of
associated adaptor proteins, and downstream sign-
aling events including MAPK/ERK activation, and
cellular proliferation. Of interest, the overexpres-
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sion of PTPROt also inhibits lymphoma-cell pro-
liferation and induces apoptosis in the absence of
BCR cross-linking, suggesting that PTPROt mod-
ulates tonic BCR signaling. The functional conse-
quences of PTPROt overexpression, including
decreased SYK phosphorylation, BCR signaling,
and cellular proliferation, highlight its likely role
in quiescent naive and memory B cells. These
observations are of additional interest as SYK is
required for B-cell maturation, follicle entry, and
recirculation [40, 62–64].
3. BCL6 transcriptional program
in “BCR”-type DLBCL
Increased expression and more common trans-
locations of BCL6 in “BCR” tumors suggested that
these tumors would exhibit differential regulation
of BCL6 target genes that would identify tumors
specifically driven by BCL6 and sensitive to BPI
treatment. For these reasons, a ChIP-on-chip ap-
proach was utilized to identify BCL6 target genes
in an aggressive B-cell lymphoma cell line and as-
sess their expression and biological function in
“BCR” tumors. The BCL6 target gene list was en-
riched in genes regulating transcription, DNA da-
mage responses, chromatin modification, cell cyc-
le and protein ubiquitylation (Table 1). Since the
mechanism(s) through which BCL6 mediates the
germinal center reaction and lymphomagenesis are
largely unknown, these data provide new insights
regarding BCL6 function in these processes. In
more recent studies, BCL6 was shown to regulate
similar functionally coherent set of pathways invo-
lved in DNA repair, cell cycle, chromatin formation
and regulation, protein stability and transcriptional
regulation in both normal GC cells and in DLBCL
[65]. However, deregulation of BCL6 in DLBCL
results in gain of many target genes, implying an
expansion of the BCL6 function in lymphoma cells
compared to their normal counterparts [65].
BCL6 target genes were coordinately repres-
sed in “BCR” tumors, indicating that the BCL6 si-
gnature contributes to the difference between
“BCR” and other molecular tumor classes that are
not BCL6-dependent. In addition, BPI treatment
increased the expression of each of these BCL6
targets in the “BCR” DLBCL cell lines but did not
alter the expression of these genes in other tumor
types. These data suggest that BCL6 is biological-
ly active in “BCR”, but not in “non-BCR”, tumors
and show that BCL6 represses its target genes in
“BCR” DLBCL regardless of their baseline levels.
Finally, the “BCR” consensus cluster designation
was more accurate in predicting BPI sensitivity than
either BCL6 protein expression alone or the abso-
lute levels of BCL6 target genes.
Taken together, this approach, combining
stringent genomic localization by ChIP on chip with
large-scale functional genomics and the use of
a specific transcription factor inhibitor highlights the
important contribution of an oncogenic transcription
factor to the transcriptional programming of a hu-
man tumor. From a clinical standpoint, these data
indicate that patients with “BCR” DLBCL may re-
present the best candidates for therapeutic trials of
BCL6 inhibitors. Standard diagnostic methods will
not delineate these patients. Development of me-
thods to identify tumors most likely to respond to
targeted therapy is an important advance since it
allows for molecular stratification of patients to the-
rapeutic arms. More broadly, these data show how
integration of genome-wide transcription factor bin-
ding and gene expression profiling can provide im-
portant insights into tumor biology, identify the
presence of gene regulatory programming by on-
cogenic transcription factors, and direct selection
of tumors for targeted therapeutic agents.
4. Characterization of BCL6 role in
promoting BCR signaling
Since the same transcriptionally defined sub-
set of DLBCL relies upon SYK-dependent BCR si-
gnaling and exhibits coordinate BCL6-mediated
transcriptional repression, the relationship betwe-
en these two processes was explored. These stu-
dies demonstrated that in normal GC B cells,
PTPROt is repressed by BCL6. The finding that
BCL6 suppresses PTPROt identifies a novel func-
tion for BCL6 in normal GC B cells. Within the GC,
centroblasts proliferate rapidly and undergo soma-
tic hypermutation of their immunoglobulin genes,
which is the basis for affinity-maturation of antibo-
dies [4, 22]. BCL6-mediated repression of the SYK
phosphatase, PTPROt, likely lowers the threshold
for tonic and ligand-induced signals from low-affi-
nity BCRs in GC B cells, facilitating their survival.
Once high-affinity BCRs are generated, enhanced
ligand-induced BCR signaling promotes BCL6 do-
wnregulation via MAPK-dependent phosphoryla-
tion of BCL6 PEST domains and associated prote-
asomal degradation, licensing exit from the GC [39].
The tight spatio-temporal control of BCR signa-
ling by BCL6 is likely altered in DLBCL with dere-
gulated BCL6 expression. In DLBCL with the con-
stitutive expression of BCL6, repression of
PTPROt augments SYK-dependent BCR signaling.
These observations identify a novel BCL6-depen-
dent pro-survival pathway in B-cell lymphomage-
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nesis. Since BCL6 and SYK are both promising ra-
tional therapeutic targets in the same group of
DLBCL, combined inhibition of these functionally
related pathways warrants further study.
Conclusions
1. Molecular signature of the “BCR” type DLBCL
has biological and functional background in the
constitutive activity of the BCR pathway. To-
nic SYK-dependent signaling is a critical survi-
val pathway in these DLBCL and can be thera-
peutically targeted with a specific ATP-compe-
titive inhibitor of SYK (R406),
2. SYK activity is physiologically controlled by
a tissue-specific and developmentally regula-
ted protein tyrosine phosphatase (PTPROt).
Overexpression of the phosphatase blocks pro-
ximal BCR signaling and downstream events
and induces cell apoptosis,
3. “BCR”-type DLBCL exhibit coordinate regu-
lation of the identified BCL6 target genes.
BCL6 signature and “BCR” subtype designa-
tion have important functional consequences
because disruption of the BCL6 transcriptio-
nal program with peptide-mediated interferen-
ce specifically inhibits growth of “BCR”-type
cell lines,
4. BCR signaling and BCL6-mediated transcrip-
tional repression are functionally related in
“BCR”-type DLBCL. In this tumor subtype,
the constitutive expression of BCL6 represses
PTPROt and augments SYK-dependent BCR
signaling. These observations identify a novel
BCL6-dependent pro-survival pathway in
B-cell lymphomagenesis and highlight the
possible synergism of combined inhibition of
these functionally related pathways.
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Figure 1. The SYK inhibitor, R406, induces apoptosis in a subset of DLBCL cell lines. DLBCL cell lines were cultured
with 1 mM or 4 mM of R406 or vehicle alone for 96 hours. Thereafter, cellular apoptosis was assessed using annexin
V–FITC/propidium iodide (PI) staining. All of the R406-sensitive cell lines (left panel) were previously designated as
“BCR-type” DLBCL using the cell line transcriptional profiles and a recently described ensemble comprehensive
cluster classifier [34]. None of the R406-insensitive cell lines were identified as “BCR-type” (“Other”, right panel)
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Figure 2. BCR signaling is intact in R406-sensitive DLBCL cell lines. (A) SYK domains and key tyrosine residues. The
SYK tandem SH2 domains (black boxes), the linker region (aa 264-370), and the kinase domain (gray box) are shown.
N indicates NH2-terminal; C, C-terminal; Y, tyrosine; P, phosphorylation. Following BCR engagement, LYN induces
phosphorylation of SYKTyr348 and Tyr352 in the linker region. Thereafter, SYK undergoes autophosphorylation of
SYKTyr525/526 and associated activation. (B). Tonic BCR signaling in R406-sensitive and -resistant DLBCL cell lines.
Single-cell phospho-specific flow cytometry was used to assess low-level SYK348 and 352 and BLNK phosphoryla-
tion in the absence (green) or presence (red) of BCR crosslinking (10 min) in R406-sensitive (B) and -resistant (C)
DLBCL cell lines. Cells stained with an isotype-matched control Ig are shown in black. The x-axis denotes expression
(log scale) and the y-axis indicates cell number
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Figure 3. R406 inhibits tonic BLNK tyrosine phosphorylation in DLBCL cell lines. DLBCL cell lines were treated with
4 mM of R406 (blue) or vehicle alone (green) at 37°C for 16 hours without crosslinking the BCR receptor (-BCR). Tonic
BLNK phosphorylation in R406- or vehicle- treated cells was detected by single-cell phospho-flow cytometry. Gray
lines represent cells stained with an isotype-matched control Ig
+ R406, – BCR
63www.jtm.viamedica.pl
Przemysław Juszczyński, B-cell receptor activity and BCL6 transscriptional program in diffuse large B-cell lymphoma
Figure 4. BCR signaling in primary DLBCL. Cryopreserved tumor cell suspensions were thawed and viable tumor
cells were isolated from a Ficoll Hypaque monolayer. Thereafter, the tumor cell suspensions were over 90% viable
by Trypan blue staining. Light microscopy, light scatter analysis at flow cytometry, and cell-surface Ig expression
confirmed the presence of a predominant population of tumor cells. (A,B) BCR signaling in primary DLBCL. Single-
-cell phospho-flow cytometry was used to assess pSYK352 and pBLNK expression in the absence (green) or presence
(red) of BCR crosslinking or BCR crosslinking following R406 treatment (blue). Primary DLBCL with intact BCR signaling
(A) and ineffective BCR signaling (B) are shown. Cells stained with isotype-matched control Ig are shown in gray
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Figure 6. PTPROt inhibits ERK phosphorylation. Tet-inducible FLAG-tagged WT or mutant (DA and CS) PTPROt
clones were cultured with or without Dox, serum starved, and stimulated with goat anti–human IgG (10 µg/mL) for 8
minutes or left untreated. Thereafter, total cell lysates were size fractionated, blotted, and analyzed with anti-
-phospho-ERK1/2 antibody (top panel). The blot was then stripped and reprobed with anti-ERK1 (middle panel) and
anti-FLAG antibodies (bottom panel)
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Figure 5. PTPROt inhibits SYK tyrosyl Y352 phosphorylation. Tet-inducible FLAG-tagged WT or mutant (CS) PTPROt
clones were cultured with or without Dox and stimulated with goat anti–human IgG for 5 (A), 15 (B) minutes, or left
untreated. Thereafter, cells were lysed and immunoprecipitated with anti-SYK or anti-CD79a antibody. Immunopreci-
pitates were size fractionated, blotted, and analyzed with indicated phosphotyrosine antibodies (a pSYK352,
pSYK525/526, pSYK323, 4G10). The blots was subsequently stripped and blotted with an anti-pan SYK or anti-CD79a
antibody. In each experiment, the corresponding whole cell lysates were simultaneously size-fractionated, blotted,
and analyzed with FLAG antibody to confirm Dox-induced overexpression of WT-PTPROt or CS-PTPROt
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Figure 7. PTPROt overexpression inhibits cellular proliferation and induces apoptosis. (A) Cellular proliferation of
tet-inducible PTPROt clones. Tet-inducible FLAG-tagged WT, CS, or DA PTPROt clones were cultured with or without
Dox for 1 to 4 days (x-axis) and analyzed in MTT proliferation assays. Proliferation on days 2 to 4 is represented as
fold increases compared with the initial day-1 measurement (y-axis). (B) Apoptosis of tet-inducible PTPROt clones.
Tet-inducible FLAG-tagged WT, CS, or DA PTPROt clones were cultured with or without Dox for 4 days and analyzed
thereafter with annexin V–FITC/PI staining. (x- and y-axes, respectively). The percentages of cells staining with PI
alone (G1), annexin V and PI (G2), annexin V alone (G4), or neither reagent (G3) are indicated
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Figure 8. Validation of candidate BCL6 target genes by quantitative ChIP assay. Forty-four (out of 54 tested)
candidate BCL6 target genes were validated. The X axis represents the fold enrichment for each promoter region vs.
IgG control antibody after normalization to input DNA. The target gene amplicons represent the enriched regions
based on the localization of the BCL6 peak on the ChIP on chip array. CCL3 and FCER2 are known BCL6 target genes
that were enriched by ChIP on chip and are included as positive controls (green); CD20 is included as negative
control (fold enrichment = 1, red)
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Figure 9. BCL6 target genes in primary “BCR” and “non-BCR” DLBCL and DLBCL cell lines. The top-scoring BCL6
target genes from the GSEA leading edge were clustered with respect to the DLBCL “BCR” and “non-BCR” phenoty-
pes and represented on a heat map in which each individual column represents a tumor and each individual row
corresponds to a gene. For comparison, the relative expression of these BCL6 target genes in normal GC B-cells is
also shown. Color scale at bottom indicates relative expression and standard deviations from the mean. (A) Primary
DLBCL heat map [9]. (B) DLBCL cell line heat map (“BCR” cells: Ly1, Ly7, SU-DHL4, SU-DHL6 and Farage; “non-BCR”
cells: Ly 4, Toledo, Kaspas 422 and Pfeiffer). (C) BCL6 target gene abundance in “BCR” and “non-BCR” cell lines
following BPI treatment. “BCR” (SU-DHL6, SU-DHL4) and “non-BCR” (Toledo, Ly4) cell lines were treated with 20 mM
of BPI or control peptide for 8 hours and the transcript abundance of the indicated BCL6 targets was evaluated with
real–time (RT) PCR thereafter. The Y axis indicates fold activation of genes after treatment with BPI vs. control
peptide based on the DDCt normalized to the expression of HPRT. BPI treatment increased the expression of each
BCL6 target gene in the “BCR” cell lines but did not alter the expression of these genes in “non-BCR” lines. BPI
treatment increased the abundance of BCL6 targets that were less abundant in “BCR” than “non-BCR” cells at
baseline (SuB1, ZNF443, CR1, CBX3, shaded in blue) and others that were more abundant in “BCR” tumors at
baseline (CD74, CCN1, MBD1, shaded in red). A known BCL6 target gene FCER2 was used as a positive control
(shaded in pink)
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Figure 11. Reciprocal patterns of PTPROt and BCL6 expression in normal B cells and primary DLBCL. (A) Relative
BCL6 and PTPROt transcript abundance in two independent series of highly purified normal B-cells (naïve, GC
centroblasts [CB] and centrocytes [CC], memory). (B) Relative BCL6 and PTPROt transcript abundance in two large
independent series of newly diagnosed and previously profiled DLBCL [9, 10]. Normal GC B cells that were profiled at
the same time [9] were included for comparison (left). Comprehensive cluster designations (“BCR”, “OxP” and “HR”)
for the primary DLBCL and normal GC cells in Monti series are indicated above the heat map. Color scale at bottom
indicates relative expression and standard deviations from the mean. Red connotes high-level expression; blue
indicates low-level expression
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Figure 10. “BCR” and “non-BCR” DLBCL cell lines display differential sensitivity to BPI. (A) BPI IC50 for “BCR” and
“non-BCR” DLBCL cell lines. “BCR” and “non-BCR” cell lines were exposed to increasing doses of BPI and cellular
proliferation was assessed at 48 hours. The IC50 and SEM for triplicate samples of each cell line in a representative
experiment are shown. (B) Mean BPI IC50 (± SD) for “BCR” and “non-BCR” DLBCL cell lines. (C) Proliferation of BPI-
-treated “BCR” and “non-BCR” DLBCL cell lines following BPI treatment. Cell lines were exposed to 20 mM BPI for 48
hours and cellular proliferation was evaluated thereafter
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Figure 12. PTPROt transcription is regulated by BCL6. (A) BCL6 represses PTPROt promoter-driven transcription
in a dose-dependent manner. A PTPROt promoter luciferase reporter construct (pGL3-Luc-PTPROt-1108+381) was
cotransfected with empty vector or increasing does (5–100 ng) of a BCL6 expression vector (pMT2T-HA-BCL6) into
HEK293T cells. Luciferase activities were evaluated as described (Methods). (B) WT-BCL6 but not BCL6 mutants
repress PTPROt promoter-driven transcription. pGL3-Luc-PTPROt-1103+381 was cotransfected with vectors enco-
ding either HA-BCL6 or one of two BCL6 mutants lacking either the amino-terminal transcriptional repressor domain
(BCL6-ZF) or carboxy-terminal DNA binding zinc-finger domain (BCL6-DZF) and luciferase activities were determined
thereafter. In both A and B, representative luciferase activities from three independent experiments were normalized
to Renilla luciferase activity and represented as fold change ± standard deviation
Figure 13. BCL6 represses PTPROt via direct interactions with the PTPROt promoter region. (A) BCL6 binds to the
PTPROt promoter in vivo. Chromatin immunoprecipitation was performed in two DLBCL cell lines (DHL4 and DHL6)
using BCL6 antibody or normal IgG as control. The target amplicons in the PTPROt promoter include the 3 predicted
BCL6 binding sites (BS1-3, solid boxes) and two distant upstream or downstream control regions (C1 and C2, open
boxes). The BCL6 vs. IgG ratio was calculated for each region and normalized to control region 1. (B) BCL6-mediated
repression of PTPROt promoter requires intact BCL6 binding sites. PTPROt-promoter-driven luciferase constructs
with or without the individual or combined mutations in the predicted BCL6 binding sites were cotransfected with
pMT2T-HA-BCL6 into HEK293T cells. Luciferase activities were determined thereafter
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Figure 14. BCL6 regulates PTPROt expression in normal naïve B-cells, GC centroblasts and certain DLBCL. (A)
Normal B cells. Normal naïve B-cells were transfected with a GFP-BCL6 construct or empty vector and GC centrobla-
sts were transduced with a BCL6-shRNA lentiviral vector or scrambled control. (B) DLBCL. A DLBCL cell line (DHL4),
was transduced with BCL6 siRNA. In both the normal B cells (A) and the DLBCL cell line (B), BCL6 protein levels were
assessed by western blot (top panel) and PTPROt expression was evaluated by RT PCR (bottom panel). In DLBCL,
expression levels of total SYK, upstream BCR pathway component CD79a and downstream adapter protein BLNK
were also evaluated
Figure 15. BCL6-mediated repression of PTPROt increases tonic BCR signaling. The DLBCL cell line, DHL4, was
transduced with BCL6-siRNA, SCR control oligonucleotides or left untreated. Cells were subsequently incubated for
72 h and stimulated with goat anti–human IgG (10 mg/mL) for 1 minute or left untreated. (A) Western analysis of SYK
phosphorylation following BCL6 depletion. BCR-crosslinked cells were lysed and immunoprecipitated with anti- SYK.
Immunoprecipitates were size-fractionated, blotted, and analyzed thereafter with a-pSYK Y352 antibody. The mem-
brane was subsequently stripped and blotted with an anti-pan SYK antibody. (B) Phospho-specific flow cytometric
analysis of tonic and a-Ig induced SYK Y352 and BLNK Y84 phosphorylation following BCL6 depletion. SYK Y352 and
BLNK Y84 phosphorylation (top and bottom panels) was compared in cells transduced with BCL6-siRNA (red), SCR
control oligonucleotides (blue) or left untreated (green) in the absence (left panel) or presence (right panel) of BCR
crosslinking. Cells stained with an isotype-matched control Ig are also shown (gray dashed line). The x-axis denotes
expression (log scale) and the y-axis indicates cell number
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